25-9326-42

antibody from Invitrogen Antibodies

Targeting: EPCAM 17-1A, 323/A3, CD326, CO-17A, EGP-2, EGP34, EGP40, Ep-CAM, ESA, GA733-2, HEA125, KS1/4, KSA, Ly74, M4S1, MH99, MIC18, MK-1, MOC31, TACST-1, TACSTD1, TROP1

Provider product page for 25-9326-42

Flow cytometry

Other assay

Antibody data

Antibody Data
Antigen structure
References [20]
Comments [0]
Validations
Flow cytometry [1]
Other assay [13]

Submit

Product number: 25-9326-42 - Provider product page
Provider: Invitrogen Antibodies
Product name: CD326 (EpCAM) Monoclonal Antibody (1B7), PE-Cyanine7, eBioscience™
Antibody type: Monoclonal
Antigen: Other
Description: Description: EpCAM (Epithelial cell adhesion molecule, CD326, KSA, TROP1) is a 40 kD cell-surface adhesion molecule participating in homophilic, calcium-independent cell-cell interactions. EpCAM is a type-I transmembrane protein, and is expressed primarily on the basolateral surface of most epithelia. Although normal epithelia express low levels of EpCAM, increased expression has been correlated with increased proliferation and progression to a mesenchymal phenotype. EpCAM has also been used as a diagnostic marker on circulating metastatic carcinoma cells, while cancer cells of non-epithelial origin do not express EpCAM.
Antibody clone number: 1B7
Concentration: 5 µL/Test

EPCAM protein structure - 25-9326-42 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 5 FZD5 maintains stem cell-like properties. A CD133, EPCAM, ALDH1A2, and POU5F1 expression in MDA-MB-231 cells was detected by real-time PCR. B Fractions of CD133-positive and EPCAM-positive MDA-MB-231 cells were detected by flow cytometry. C Mammosphere formation of MDA-MB-231 cells was shown. Scale bar: 500 mum, mean +- SD, n = 3. * P < 0.05, ** P < 0.01, *** P < 0.001, vs. shCtrl. D CD133, EPCAM, ALDH1A2, and POU5F1 expression in Hs-578t cells was detected by real-time PCR. E Fractions of CD133-positive and E PCAM-positive Hs-578t cells were detected by flow cytometry. F Mammosphere formation of Hs-578t cells was shown. Scale bar: 500 mum, mean +- SD, n = 3. * P < 0.05, ** P < 0.01, *** P < 0.001, vs. OE Ctrl.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Multiparametric flow cytometry of PBMCs capturing uPAR/int beta1 CTC subsets. Breast cancer PBMCs were first sorted applying gating parameters to select for DAPI - (4', 6-diamidino-2-phenylindole)/EpCAM - /CD45 - /CD44 + /CD24 - cells. Cells were then subsequently sorted to obtain uPAR/int beta1 subsets containing combinatorial expression of these markers. Antibodies used for flow cytometry and cell sorting were: anti-human CD45-APC-Cy7 (Biolegend, cat # 304015, 1:50 dilution), mouse anti-human EpCAM-PE CD326 (eBiosciences, cat # 12-9326-71, 1:40 dilution), anti-human CD24-PE ML5 (Biolegend, cat # 311106, 1:20 dilution), anti-human CD44-PE-Cy7 IM7 (Biolegend, cat # 103030, 1:20 dilution), mouse anti-human uPAR (CD87)-FITC (AbD Serotec cat # MCA2506FT, 1:10 dilution), anti-human int beta1 (CD29)-ApC TS2/16 (Biolegend, cat # 3030008, 1:50 dilution). Cells were confirmed to be CTCs by performing RT-PCR, immunoflurescence and genotyping arrays. Representative images are shown.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 8 Elevated IL-17RB expression in cancer cells derived from tumor-draining lymph nodes in breast cancer patients correlates with aggressive growth nature A Freshly collected human breast cancer (hBC) specimens (PT, primary tumors; LN, paired LN metastasis from the same breast cancer patient) were digested with collagenase-containing buffer overnight. Depletion of hematopoietic cells by CD45 Dynabeads (Invitrogen) enriched the EpCAM + cells for following xenografts. Percentages of EpCAM + cells in human primary breast cancer cells were confirmed by FACS analysis (left two panels: before enrichment; right two panels: after enrichment). All of the histograms were shown that they were EpCAM expressing (black line), compared to isotype control (gray filled). B Tumorigenesis assay was determined in NOD/SCID/IL2Rgamma mice orthotopically injected with hBC PT and hBC LN cells. Representative data on day 180 were shown. White arrow: Orthotopic injection site. C Dot plot illustrated the tumor volumes of hBC PT and hBC LN cell-injected NOD/SCID/IL2Rgamma mice on day 180 ( n = 11). All tumors were confirmed by pan-keratin IHC staining of fat pad sections. D, E H&E stainings and IHC stainings of pan-keratin were shown in the representative cases of fat pad sections from (B). Scale bar: 1 mm (left panels), 100 mum (right panels). F IHC stainings of IL-17RB were shown in the representative cases of fat pad sections from (B). Scale bar: 10 mum. G The correlatio

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 4 EMP3 interferes with stem-like properties. A CCLE database was interrogated for EMP3, SOX2, CD133, and EPCAM expression. Correlation between two genes in a total of 57 breast cancer cell lines was analyzed by Pearson statistics. B SOX2, CD133, and EPCAM expression in MDA-MB-231 cells were detected by real-time PCR. Mean +- SD, n = 3. * P < 0.05, ** P < 0.01, *** P < 0.001, vs. shCtrl. C Fractions of CD133-positive MDA-MB-231 cells were detected by flow cytometry. Mean +- SD, n = 3. ** P < 0.01, vs. shCtrl. D Fractions of EPCAM-positive MDA-MB-231 cells were detected by flow cytometry. Mean +- SD, n = 3. ** P < 0.01, vs. shCtrl. E Mammosphere formation of MDA-MB-231 cells was shown. Mean +- SD, n = 3. ** P < 0.01, *** P < 0.001, vs. shCtrl. F Mammosphere formation of MCF7 cells was shown. Mean +- SD, n = 3. ** P < 0.01, vs. OE Ctrl. G SOX2, CD133, and EPCAM expression in MCF7 cells were detected by real-time PCR. Mean +- SD, n = 3. *** P < 0.001, vs. OE Ctrl.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Generation of proximal lung organoids from cystic fibrosis patient iPSCs (A) Schematic representation of lung organoid differentiation protocol from human iPSCs (hiPSCs). (B) Representative immunofluorescence staining for p63 (green), NKX2.1 (red), SOX2 (red), and nuclear protein expression with DNA stain (DAPI; blue) in HLOs on day 20 (p63 and NKX2.1) and day 22 (SOX2). Scale bars represent 100 mum. (C) Flow cytometry analysis of EpCAM expression in organoid cells on day 23. Left: summary percentage of EpCAM-positive cells. Three independent HLO plates were used for the experiment. Data are presented as mean +- standard error of the mean (SEM). Right: a representative flow cytometry result. The x axis indicates the count of cells, and the y axis indicates EpCAM signal level.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 1 Identification of three major epithelial cell types and their markers using scRNAseq. a Overview of scRNAseq approach using primary human breast tissue samples that were processed into single cell suspension, followed by FACS isolation of basal (CD49f-hi, EPCAM+) and luminal (CD49f+, EPCAM-hi), and scRNAseq analysis using the microfluidics-enabled scRNAseq. b Combined tSNE projection of cells from all three microfluidics-enabled scRNAseq datasets. The major basal cluster is highlighted in red; Luminal1 (L1) in green; Luminal2 (L2) in blue. c Heatmap displaying the scaled expression patterns of top marker genes within each cell type with selected marker genes highlighted; yellow indicating high expression of a particular gene, and purple indicating low expression. d Feature plots showing the scaled expression of TCF4 and ZEB1 marking a subpopulation of basal cells and gene plot showing co-expression of TCF4 and ZEB1 in the same cells. See Supplementary Fig. 1 capture site imaging, gene detection, individual principal component analysis, tSNE plot colored by individual-derived cells and feature plots of cell type-specific markers

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Characterization of BCSC5 in vitro and in vivo. ( A ) Representative pictures of BCSC5 cultured in 3D and 2D conditions, scale bar 100 mum. ( B ) Sphere-forming capacity of BCSC5 cells in an anchorage-independent growth assay ( n = 3). Data represent means + SEM. ( C , D ) Expression patterns of CD24 and CD44 ( C ) as well as EpCAM and CD49f ( D ) in BCSC5 cells analyzed by flow cytometry. ( E ) Tumor formation in limiting dilution xenografts of BCSC5. ( F ) Representative growth curves for limiting dilution assay of BCSC5 xenografts in immunocompromised NOD/SCID mice. ( G ) Immunohistochemical (IHC) analysis of ER, PR, and HER2 on sections of the BCSC5 xenograft tumors, scale bar 100 mum.